Table 6. NCI Common Toxicity Criteria Version 3.0 Non-dermatological Adverse Events Relevant to EGFR Inhibition.

Grade
Symptom 1 2 3 4 5
Diarrhea Increase of < 4 stools per day over baseline.
Mild increase in ostomy output compared to baseline		 Increase of 4 - 6 stools per day over baseline;
IV fluids indicated < 24 hrs;
Mod increase in ostomy output compared to baseline;
Not interfering with ADL		 Increase of > 7 stools per day over baseline;
Incontinence;
IV fluids > 24 hrs;
hospitalization;
Severe increase in ostomy output compared to baseline;
Interfering with ADL		 Life-threatening consequences (e.g., hemodynamic collapse) Death
Hypomagnesemia <LLN - 1.2 mg/dL;
<LLN - 0.5 mmol/L;
LLN:
Lower;
Limit Normal		 <1.2 - 0.9 mg/dL;
<0.5 - 0.4 mmol/L		 <0.9 - 0.7 mg/dL;
<0.4 - 0.3 mmol/L		 <0.7 mg/dL;
<0.3 mmol/L		 Death
Pneumonitis/pulmonary infiltrates Pneumonitis asymptomatic, radiographic findings only Symptomatic, not interfering with ADL Symptomatic, interfering with ADL; O2 indicated Life-threatening; ventilatory support indicated Death